Investing.com -- The U.S. Centers for Medicare & Medicaid Services (CMS) on Tuesday announced a new list of branded medications for the third round of the Medicare Drug Price Negotiation Program. The ...

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

My top 10 things to watch Tuesday, Jan. 27 1. The S & P 500 was headed for a slightly higher open this morning ahead of Big Tech earnings tomorrow evening (Meta Platforms and Microsoft ) and Thursday ...

Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach ...

Now, it’s worth noting Stock Advisor’s total average return is 949 % — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

The S&P 500 rose as traders braced for a big week, with key earnings reports and a U.S. monetary policy meeting.

In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change lagged the S&P 500's 0.03% gain on the day. Elsewhere, the Dow saw a ...

Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

US markets closed higher last night, thanks to a slight thaw in geopolitical tensions. Solid US economic data also lifted sentiment. Big-tech rallied thanks to an upbeat speech by Jensen Huang at ...

Eli Lilly ( LLY 2.05%) delivered a gain worthy of a technology growth stock last year. The pharma giant's shares soared 39%, ...